Alnylam breaks ground on new manufacturing facility in Norton, Massachusetts
200,000 sq ft state-of-the-art biopharmaceutical manufacturing facility supports expanding development pipeline and transition toward commercial stage.
Alnylam Pharmaceuticals has broken ground on a state-of-the-art biopharmaceutical manufacturing facility in Norton, Massachusetts. The facility will supply RNAi therapeutics for Alnylam’s clinical and commercial needs. The location, selected in close collaboration with Commonwealth and local officials, demonstrates Alnylam’s ongoing commitment to Massachusetts. Construction on the 200,000 sq ft manufacturing facility is expected to complete in 2018 and it will initially employ approximately 150 new full-time employees.
“This flagship multi-product facility represents a key next step in Alnylam’s transition toward a commercial stage company. Increased manufacturing capability is vital to support our rapidly growing pipeline of 10 clinical stage programs, two of which are in Phase III trials,” said John Maraganore, CEO of Alnylam. “The Massachusetts talent pool, along with strong support from state and local partners in the Baker Administration, Massachusetts Life Sciences Center, and the Town of Norton were critical to our ultimate decision to establish this manufacturing facility in Norton, MA.”
Speaking at the groundbreaking ceremony are Charlie Baker, the Governor of Massachusetts, Kimberly Haugstad, Executive Director of the Hemophilia Federation of America, Travis McCready, President and CEO of the Massachusetts Life Sciences Center and Lisa Nelson, Senior District Representative to US Congressman Joseph Kennedy III.
“Alnylam’s decision to locate their biopharmaceutical manufacturing facility in Massachusetts speaks to our Commonwealth’s success in supporting an innovative economic environment and talented workforce,” said Governor Charlie Baker. “We are excited about Alnylam’s choice and congratulate them as they continue to grow and advance investigational new medicines in the Commonwealth’s life sciences sector, creating new jobs and patient treatments.”
"The development of Alnylam’s manufacturing facility in Norton is further evidence that the State of Massachusetts can support the needs of integrated biotechnology companies such as Alnylam, through the entire biopharmaceutical life cycle, from discovery to development to manufacturing to sales and marketing,” said Travis McCready, President and CEO, Massachusetts Life Sciences Center.
“The Hemophilia Federation of America is dedicated to serving the needs of patients and families affected by hemophilia and other rare bleeding disorders,” said Kimberly Haugstad, Executive Director of the Hemophilia Federation of America. “With the development of this manufacturing facility, Alnylam demonstrates its commitment and responsibility to the patient community as it strives to provide innovative new treatment options.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance